Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11425856 | 0.81 | ELANE (0.53) | GLAMEN1KMT2AELANESMN1; SMN2 | |
| SCHEMBL15679080 | 0.81 | ELANE (0.55) | MEN1KMT2AALDH1A1LMNAELANE | |
| SCHEMBL23493150 | 0.81 | ELANE (0.55) | MEN1KMT2AALDH1A1LMNAELANE | |
| SCHEMBL4104242 | 0.80 | MEN1 (0.55) | GLAMEN1KMT2AALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL30184762 | 0.79 | ELANE (0.53) | MEN1KMT2AALDH1A1LMNAELANE | |
| SCHEMBL10504279 | 0.79 | RXFP1 (0.56) | GLAMEN1KMT2AALDH1A1GAA | |
| SCHEMBL10504965 | 0.79 | TGM2 (0.60) | GLAMEN1KMT2AALDH1A1GAA | |
| SCHEMBL4806554 | 0.79 | PRSS1 (0.52) | ELANE | |
| SCHEMBL11440483 | 0.77 | KMT2A (0.41) | GLAMEN1KMT2AALDH1A1GAA | |
| SCHEMBL11427464 | 0.77 | FPR2 (0.48) | KMT2ALMNASMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941526-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH A GLYCINE BASED LINKER | Paul Scherrer Institut (CH) | 2022-01-26 | — | — | EP | disclosed |
| EP-3755711-A1 | IMMUNOTHERAPEUTIC COMPOSITION FOR THE TREATMENT OF CANCER | Technion Research & Development Foundation Limited (IL) | 2020-12-30 | — | — | EP | disclosed |
| US-20200385441-A1 | IMMUNOTHERAPEUTIC COMPOSITION FOR THE TREATMENT OF CANCER | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2020-12-10 | — | — | US | disclosed |
| WO-2020188061-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH A GLYCINE BASED LINKER | PAUL SCHERRER INSTITUT (CH) | 2020-09-24 | — | — | WO | disclosed |
| WO-2019162937-A1 | IMMUNOTHERAPEUTIC COMPOSITION FOR THE TREATMENT OF CANCER | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2019-08-29 | — | — | WO | disclosed |
| US-20190031759-A1 | CHIMERIC ANTIGEN RECEPTORS AND METHODS OF THEIR USE | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2019-01-31 | — | — | US | disclosed |
| EP-1409547-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNE DECEPTION, PARTICULARLY USEFUL IN THE TREATMENT OF CANCER | TECHNION RES & DEV FOUNDATION (IL) | 2017-09-20 | — | — | EP | disclosed |
| US-20170198046-A1 | COMPOSITIONS CAPABLE OF SPECIFICALLY BINDING PARTICULAR HUMAN ANTIGEN PRESENTING MOLECULE/ ANTIGEN COMPLEXES AND USES THEREOF | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2017-07-13 | — | — | US | disclosed |
| WO-2016174652-A1 | CHIMERIC ANTIGEN RECEPTORS AND METHODS OF THEIR USE | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2016-11-03 | — | — | WO | disclosed |
| EP-2970289-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-6544759-B1 | Genetic engineering; isolated nucleic acid | YEDA RESEARCH AND DEVELOPMENT CO. LTD (IL) | 2003-04-08 | — | — | US | disclosed |
| US-20030017134-A1 | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. | 2003-01-23 | — | — | US | disclosed |
| WO-2002102299-A2 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNE DECEPTION, PARTICULARLY USEFUL IN THE TREATMENT OF CANCER | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002094981-A2 | METHOD OF IDENTIFYING PEPTIDES CAPABLE OF BINDING TO MHC MOLECULES, PEPTIDES IDENTIFIED THEREBY AND THEIR USES | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2002-11-28 | — | — | WO | disclosed |
| US-20020115069-A1 | EH DOMAIN CONTAINING GENES AND PROTEINS | Ramot University Authority of Applied Research and Industrial Development Ltd. (IL) | 2002-08-22 | — | — | US | disclosed |
| WO-2002055543-A2 | HYBRID PEPTIDES FOR TREATMENT OF BACTEREMIA AND SEPTICEMIA | UNIV RAMOT (IL) | 2002-07-18 | — | — | WO | disclosed |
| WO-2001081540-A2 | GROWTH FACTOR WHICH ACTS THROUGH ERB B-4 RTK | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2001-11-01 | — | — | WO | disclosed |
| EP-1100901-A1 | TUMOR ASSOCIATED ANTIGEN PEPTIDES AND USE OF SAME AS ANTI-TUMOR VACCINES | YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD. (IL) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000066707-A2 | NOVEL THIAMINE TRANSPORTER, A POLYNUCLEOTIDE ENCODING SAME AND THEIR USES | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000006723-A1 | TUMOR ASSOCIATED ANTIGEN PEPTIDES AND USE OF SAME AS ANTI-TUMOR VACCINES | YEDA RESEARCH AND DEVELOPMENT COMPANY LTD AT THE WEIZMANN INSTITUTE OF SCIENCE (IL) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115069-A1 | EH DOMAIN CONTAINING GENES AND PROTEINS | EPS15, EHD1, PITHD1 | GLA 4831/4885MEN1 1614/4885KMT2A 2620/4885 |
| US-20170198046-A1 | COMPOSITIONS CAPABLE OF SPECIFICALLY BINDING PARTICULAR HUMAN ANTIGEN PRESENTING MOLECULE/ ANTIGEN COMPLEXES AND USES THEREOF | CD74, CD14, MICA | GLA 1732/4885MEN1 1295/4885KMT2A 3470/4885 |
| US-20200385441-A1 | IMMUNOTHERAPEUTIC COMPOSITION FOR THE TREATMENT OF CANCER | CD74, MICA, HLA-C | GLA 3701/4885MEN1 3608/4885KMT2A 2977/4885 |
| US-20030017134-A1 | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer | GZMB, CD74, HLA-DRB1 | GLA 2977/4885MEN1 3558/4885KMT2A 3720/4885 |
| US-20190031759-A1 | CHIMERIC ANTIGEN RECEPTORS AND METHODS OF THEIR USE | HAVCR2, CD2BP2, CD74 | GLA 2685/4885MEN1 4333/4885KMT2A 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.